12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Benlysta belimumab: Phase III started

Human Genome said in May 2011 partner GlaxoSmithKline began a double-blind, placebo-controlled, Asian Phase III trial to evaluate 10 mg/kg IV Benlysta plus standard of care every 2 weeks for the first 3 doses and every 4 weeks thereafter in...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >